Laser breakthrough: new procedure aims to zap away nearsightedness

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male and female subjects age 22 years of age and older; * Spherical myopia from ≥ -1.00 D to ≤ -8.00 D, with ≤ -0.50 D cylinder and MRSE ≤ -8.25 D in the eye to be treated; * A stable refraction for the past year, as demonstrated by a change in MRSE of ≤ 0.50 D in the eye to be treated; * A difference between cycloplegic and manifest refractions of \< 0.75 D spherical equivalent in the eye to be treated; * UCVA worse than 20/40 in the eye to be treated; * BSCVA at least 20/20 in the eye to be treated; * Discontinue use of contact lenses for at least 2 weeks (for hard lenses) or 3 days (for soft lenses) prior to the preoperative examination, and through the day of surgery; * All contact lens wearers must demonstrate a stable refraction (within ±0.5 D), as determined by MRSE, on two consecutive examinations at least 1 week apart, in the eye to be treated; * Central corneal thickness of at least 500 microns in the eye to be treated; * Willing and able to return for scheduled follow-up examinations; * Able to provide written informed consent and follow study instructions in English. Exclusion Criteria: * Mesopic pupil diameter \> 8.0 mm; * Cylinder \> -0.50 D; * Treatment depth is less than 250 microns from the corneal endothelium; * Eye to be treated is targeted for monovision; * Fellow eye has BSCVA worse than 20/40; * Abnormal corneal topographic findings, e.g. keratoconus, pellucid marginal degeneration in either eye; * History of or current anterior segment pathology, including cataracts in the eye to be treated; * Clinically significant dry eye syndrome unresolved by treatment in either eye; * Residual, recurrent, active ocular or uncontrolled eyelid disease, corneal scars or other corneal abnormality such as recurrent corneal erosion or severe basement membrane disease in the eye to be treated; * Ophthalmoscopic signs of progressive or unstable myopia or keratoconus (or keratoconus suspect) in either eye; * Irregular or unstable (distorted/not clear) corneal mires on central keratometry images in either eye; * History of ocular herpes zoster or herpes simplex keratitis; * Deep orbits, strong blink, anxiety, pterygium, or any other finding suggesting difficulty in achieving or maintaining suction; * Difficulty following directions or unable to fixate; * Previous intraocular or corneal surgery of any kind in the eye to be treated, including any type of surgery for either refractive or therapeutic purposes; * History of steroid-responsive rise in intraocular pressure, glaucoma, or preoperative IOP \> 21 mmHg in either eye; * History of diabetes, diagnosed autoimmune disease, connective tissue disease or clinically significant atopic syndrome; * Immunocompromised or requires chronic systemic corticosteroids or other immunosuppressive therapy that may affect wound healing; * History of known sensitivity to planned study medications; * Participating in any other ophthalmic drug or device clinical trial during the time of this clinical investigation; * Pregnant, lactating, or of child-bearing potential and not practicing a medically approved method of birth control.